News & Updates
Excerpt from the Press Release: Data Reported at the 2021 Society for Immunotherapy of Cancer Annual Meeting SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today reported in vitro and in vivo preclinical…
Read More
Initial Safety and Efficacy Data for NKTR-255, a Novel IL-15 Agonist, in Combination with Cetuximab in Solid Tumors Presented in Late-Breaking Abstract Session SAN FRANCISCO, Nov. 12, 2021 /PRNewswire/ — Nektar Therapeutics (Nasdaq: NKTR) today announced three data presentations for its I-O pipeline at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting. Excerpt from the Press Release: Initial clinical…
Read More
21.4% Overall Response Rate (ORR) in Heavily Pre-Treated Patients with Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer (mNSCLC) Conference Call and Webcast on Saturday, November 13 at 5:30pm ET Excerpt from the Press Release: SAN CARLOS, Calif., and WASHINGTON, Nov. 12, 2021 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel…
Read More
Debut data presented at SITC 2021 demonstrate target-dependent cytotoxic function as well as innate immune functions of antigen capture and APC-like activity Multifunctionality suggests potential for improved tumor clearance and durability of response over existing cell-based therapies Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–CERo Therapeutics, Inc., a biopharmaceutical company pioneering the development…
Read More
Data support ability of AU-007, a computationally evolved, human IgG1 monoclonal antibody, to specifically block IL-2’s binding to CD25 and inhibit tumor growth in multiple cancer models Data show potential of novel cancer treatment to break negative feedback loop caused by IL-2 and prevent Treg expansion Excerpt from the Press Release: LARKSPUR, Calif.–(BUSINESS WIRE)–Aulos Bioscience,…
Read More
—Selective targeting of IL-2, a potent immunomodulator, to CD8+ T cells results in enhanced anti-tumor activity across multiple in vivo animal models and an enhanced safety profile — — IND filing for AB248 on-track for 3Q 2022 — Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Asher Biotherapeutics, a biotechnology company developing precisely-directed immunotherapies…
Read More
–Publication highlights first ever, most comprehensive data-driven neurobiological mapping of the mind– –Findings, published in Nature Neuroscience, validate Alto’s rigorous high-science approach and may be translated to future drug discovery and development– –Intellectual property has been exclusively licensed to Alto by Stanford– Excerpt from the Press Release: LOS ALTOS, Calif.–(BUSINESS WIRE)–Alto Neuroscience today announced the publication of the…
Read More
Excerpt from the Press Release: Data showed Amphiphile (AMP) boosting significantly enhanced TCR-T cell anti-tumor efficacy and led to durable responses against solid tumors in an established, syngeneic tumor model AMP boosting of CD19-specific CAR-T cells led to enhanced CAR-T activation and effector function suggesting the platform can potentially be utilized to improve clinical CD19…
Read More
Excerpt from the Press Release: WATERTOWN, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today presented new preclinical data from its STAT3 degrader program at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual…
Read More
Excerpt from the Press Release: Monotherapy data further enhances confidence in CUE-101 potential as single agent therapeutic in the refractory/metastatic human papillomavirus positive head and neck squamous cell carcinoma (HPV+ HNSCC) setting Early CUE-101 combination data with KEYTRUDA® (pembrolizumab) supports potential mechanistic activity CUE-102 in vivo data demonstrated ability to selectively activate and expand Wilms’…
Read MoreRequest Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?